Belinostat Patent Expiration

1. Beleodaq patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6888027 ACROTECH BIOPHARMA Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors
Aug, 2026

(2 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8835501 ACROTECH BIOPHARMA Pharmaceutical formulations of HDAC inhibitors
Oct, 2027

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 03, 2019
Orphan Drug Exclusivity(ODE) Jul 03, 2021
Orphan Drug Exclusivity(ODE-68) Jul 03, 2021

NCE-1 date: 03 July, 2018

Market Authorisation Date: 03 July, 2014

Treatment: Treatment of patients with relapsed or refractory peripheral t-cell lymphoma (ptcl).

Dosage: POWDER

How can I launch a generic of BELEODAQ before it's drug patent expiration?
More Information on Dosage

BELEODAQ family patents

Family Patents